Morgan Stanley analyst Maxwell Skor initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $115 price target The firm says ALXN1840 demonstrated “meaningful” copper mobilization and neurological benefit in a Phase 3 study as a “differentiated therapy” for Wilson’s disease with a once-daily profile. The analyst sees an “encouraging set-up” for the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
- Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
- Monopar downgraded to Outperform from Strong Buy at Raymond James
- Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
- Monopar Therapeutics reports Q EPS (48c), consensus (40c)